Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort
暂无分享,去创建一个
[1] M. Fincancı,et al. Comparison of tenofovir and entecavir in patients with chronic HBV infection. , 2013, European review for medical and pharmacological sciences.
[2] P. Marcellin,et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load , 2013, Hepatology.
[3] S. Ahn,et al. Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B , 2013, Clinical and molecular hepatology.
[4] M. Miquel,et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. , 2013, Annals of hepatology.
[5] M. Buti,et al. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B , 2012, Expert review of gastroenterology & hepatology.
[6] S. Pol,et al. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice , 2012, Journal of viral hepatitis.
[7] H. Yim,et al. KASL Clinical Practice Guidelines: Management of chronic hepatitis B , 2012, Clinical and molecular hepatology.
[8] S. Hutchinson,et al. Hepatitis B prevention, diagnosis, treatment and care: a review. , 2011, Occupational medicine.
[9] S. Ahn,et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir , 2011, Hepatology.
[10] J. Heo,et al. Partial Virological Response to Entecavir in Treatment-Naive Patients with Chronic Hepatitis B , 2011, Antiviral therapy.
[11] D. Harnois,et al. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B , 2011 .
[12] M. Manns,et al. Treatment of chronic hepatitis B. , 2010, Minerva gastroenterologica e dietologica.
[13] P. Pham,et al. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B , 2010, Expert review of anti-infective therapy.
[14] M. Yuen,et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions , 2010, Hepatology international.
[15] D. Moradpour,et al. [Management of chronic hepatitis B]. , 2010, Revue medicale suisse.
[16] A. Duarte-Rojo,et al. Review: Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B , 2010, Therapeutic advances in gastroenterology.
[17] Ronald E. Rose,et al. Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.
[18] Jörg Petersen,et al. EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.
[19] G. Dusheiko,et al. Current treatment of hepatitis B , 2007, Gut.
[20] P. Loehrer,et al. Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .
[21] Chien-Jen Chen,et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.
[22] Guan-Tarn Huang,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.
[23] Y. Paik,et al. The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B , 2005, Antiviral therapy.
[24] B. Song,et al. Hepatitis B Virus Genotypes in Korea: An Endemic Area of Hepatitis B Virus Infection , 2005, Intervirology.
[25] S. Fan,et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. , 2003, Journal of hepatology.
[26] Y. Liaw. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B , 2002, Journal of gastroenterology and hepatology.
[27] T. Berg,et al. Tenofovir treatment in patients with lamivudine‐resistant hepatitis B mutants strongly affects viral replication , 2002, Hepatology.
[28] T. Okanoue,et al. A case‐control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C , 2001, Hepatology.
[29] T. Okanoue,et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. , 2001, Hepatology.
[30] M. Romero Gómez,et al. [Current treatment of hepatitis B]. , 2001, Gastroenterologia y hepatologia.
[31] Ding‐Shinn Chen,et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. , 2000, Gastroenterology.